Literature DB >> 17396998

Progesterone inhibits HIV-1 replication in human trophoblast cells through inhibition of autocrine tumor necrosis factor secretion.

Laura Diaz Muñoz1, Maria Jesús Serramía, Manuel Fresno, Maria Angeles Muñoz-Fernández.   

Abstract

BACKGROUND: Progesterone levels are higher in placental barriers during pregnancy, but the effect of progesterone on human immunodeficiency virus type 1 (HIV-1) infection in placental cells has not been addressed. We hypothesize that progesterone may affect HIV infection.
METHODS: Purified trophoblastic cells and trophoblastic cell lines were infected or transfected with HIV-1, and the effect of progesterone was analyzed. Viral replication was measured by viral p24 or viral load quantification. Nuclear factor kappa -B (NF- kappa B) or long terminal repeat (LTR)-dependent transcription was measured by luciferase assays. Expression of chemokine receptors was analyzed by flow cytometry. Tumor necrosis factor (TNF) messenger RNA was assessed by reverse-transcription polymerase chain reaction (RT-PCR) and quantitative RT-PCR.
RESULTS: Progesterone inhibits HIV-1 replication in placental cells at the concentration found in the placental interface, at a postentry step, and does not affect cell surface expression of chemokine receptors. Progesterone did not inhibit basal or induced LTR transcription or NF- kappa B activation. TNF synthesis in placental cells is induced by HIV-1 infection that, in an autocrine manner, activates viral replication, because neutralizing anti-TNF antibodies block it. Progesterone inhibits the induction of TNF synthesis by viral infection and virus or gp-120-induced TNF transcription.
CONCLUSION: Our results demonstrate that progesterone inhibits HIV-1 replication in placental cells by reducing TNF levels, which are required for optimal viral replication.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17396998     DOI: 10.1086/513434

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  5 in total

Review 1.  Progesterone-based compounds affect immune responses and susceptibility to infections at diverse mucosal sites.

Authors:  Olivia J Hall; Sabra L Klein
Journal:  Mucosal Immunol       Date:  2017-04-12       Impact factor: 7.313

2.  Depo-provera treatment does not abrogate protection from intravenous SIV challenge in female macaques immunized with an attenuated AIDS virus.

Authors:  Meritxell Genescà; Michael B McChesney; Christopher J Miller
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

3.  Dendritic cell activation and memory cell development are impaired among mice administered medroxyprogesterone acetate prior to mucosal herpes simplex virus type 1 infection.

Authors:  Rodolfo D Vicetti Miguel; Robert L Hendricks; Alfredo J Aguirre; Melissa A Melan; Stephen A K Harvey; Tracy Terry-Allison; Anthony J St Leger; Angus W Thomson; Thomas L Cherpes
Journal:  J Immunol       Date:  2012-08-31       Impact factor: 5.422

4.  Proteasome-independent degradation of HIV-1 in naturally non-permissive human placental trophoblast cells.

Authors:  Anna Laura Ross; Claude Cannou; Françoise Barré-Sinoussi; Elisabeth Menu
Journal:  Retrovirology       Date:  2009-05-15       Impact factor: 4.602

Review 5.  Allopregnanolone and neuroHIV: Potential benefits of neuroendocrine modulation in the era of antiretroviral therapy.

Authors:  Mohammed F Salahuddin; Alaa N Qrareya; Fakhri Mahdi; Emaya Moss; Nicholas S Akins; Jing Li; Hoang V Le; Jason J Paris
Journal:  J Neuroendocrinol       Date:  2021-10-14       Impact factor: 3.870

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.